帕金森病患者血清可溶性Fas和可溶性Fas配体水平观察  

Study on serum levels of soluble Fas and soluble Fas ligand in patients with Parkinson's disease

作　　者：时鹏[1] 年娣[2] 屈洪党[1] 李强[1] 钱卫东[1] 谢静[1] 许力[1] 王春[1] 马博[1] 

机构地区：[1]蚌埠医学院第一附属医院神经内科,安徽省蚌埠市233000 [2]蚌埠医学院检验系核医学,安徽省蚌埠市233000

出　　处：《国际神经病学神经外科学杂志》2014年第3期231-234,共4页Journal of International Neurology and Neurosurgery

基　　金：安徽省卫生厅课题(KJ20132210)

摘　　要：目的观察血清中细胞凋亡蛋白可溶性Fas(sFas)与可溶性Fas配体(sFasL)的水平及其动态变化是否参与帕金森病(PD)的发生,探索PD可能的发病机制。方法60例帕金森病患者(男性34例,女性26例)为研究组,30例健康体检者(男性16例,女性14例)为对照组。用酶联免疫分析法检测两组血清sFas/sFasI水平,比较两组之间sFas/sFasI浓度的差异。结果PD组Hoehn-Yahr分级1-5级血清sFas/sFasI水平均显著高于对照组(P值均<0.05)。PD组UPDRS评分轻度、中度和重度血清sFas/sFasL水平均显著高于对照组(P值均<0.05)。PD患者血清sFas/sFasI水平呈正相关性(r=0.801;P=0.01)。结论血清sFas/sFasL的水平与PD病情严重程度有关,血清sFas/sFasL水平与PD的发病有一定的关系。Objective To investigate the roles of serum soluble Fas （sFas） and soluble Fas ligand （sFasL） in the development and progression of Parkinson＇ s disease （PD）. Methods Sixty patients with PD （26 females and 34 males） were selected as study group, and 30 healthy subjects （ 14 females and 16 males） were selected as control group. Enzyme-linked immunosorbent assay was used to measure serum levels of sFas and sFasL in both groups, and the differences in sFas and sFasL concentrations between the two groups were evaluated. Results All patients with Hoehn-Yahr stage 1-5 PD had significantly higher serum levels of sFas and sFasL than the control group （P 〈 0.05 for all）. Patients with mild, moderate, and severe PD, as evaluated according to the UPDRS scoring system, had significantly higher serum levels of sFas and sFasL than the control group （P 〈 0.05 for all）. In PD patients, serum levels of sFas and sFasL were positively correlated with each other （r = 0.801, P = 0. 01 ）. Conclusions Serum levels of sFas and sFasL are posi- tively correlated with the severity of PD. sFas and sFasL might play an important role in the pathogenesis of PD.

关 键 词：帕金森 抗原 CD95 细胞凋亡 

分 类 号：R742.5[医药卫生—神经病学与精神病学]